| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial |
|
言語 |
en |
| 作成者 |
Hatooka, Masahiro
Kawaoka, Tomokazu
Aikata, Hiroshi
Inagaki, Yuki
Morio, Kei
Nakahara, Takasi
Murakami, Eisuke
Tsuge, Masataka
Hiramatsu, Akira
Imamura, Michio
, 由育
Awai, Kazuo
Masaki, Keiichi
Waki, Koji
Kohno, Hirotaka
Kohno, Hiroshi
Moriya, Takashi
Nagaoki, Yuko
Tamura, Toru
Amano, Hajime
Katamura, Yoshio
Chayama, Kazuaki
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
HAIC |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
HCC |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
RECIST |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Sorafenib |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Tumor marker |
| 主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
| 内容記述 |
|
|
内容記述 |
[BACKGROUND]:In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase II study to assess survival with HAIC or HAIC converted to sorafenib. [METHODS]:Fifty-five patients were prospectively enrolled. Patients received HAIC as a second course if they had complete response, partial response, or stable disease (SD) with an alpha fetoprotein (AFP) ratio < 1 or a des-γ-carboxy prothrombin (DCP) ratio < 1. Patients were switched to sorafenib if they had SD with an AFP ratio > 1 and a DCP ratio > 1 or disease progression. The primary endpoint was the 1-year survival rate. Secondary endpoints were the 2-year survival rate, HAIC response, survival rate among HAIC responders, progression-free survival, and adverse events. [RESULTS]:Of the 55 patients in the intent-to-treat population, the 1-year and 2-year survival rates were 64.0 and 48.3%, respectively. After the first course of HAIC, one (1.8%) patient showed complete response, 13 (23.6%) showed partial response, 30 (54.5%) had SD, and 10 (18.1%) patients had progressive disease. Twenty-three patients (41.8%) had SD with AFP ratios < 1 or DCP ratios < 1, and 7 (12.7%) had SD with AFP ratios > 1 and DCP ratios > 1. Thirty-seven patients (68.5%) were responders and 17 (30.9%) were non-responders to HAIC. In responders, the 1-year and 2-year survival rates were 78 and 62%, respectively. [CONCLUSION]:Given the results of this study, this protocol deserves consideration for patients with advanced HCC. This trial was registered prospectively from December 12. 2012 to September 1. 2016. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
BioMed Central |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1186/s12885-018-4519-y |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1186/s12885-018-4519-y |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
29866075 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1471-2407 |
| 開始ページ |
|
|
開始ページ |
633 |
| 書誌情報 |
BMC Cancer
BMC Cancer
巻 18,
p. 633,
発行日 2018-06-04
|
| 旧ID |
47069 |
bmcc_18_633.pdf (1.0 MB)
